sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
»ùÒòÐÞÊΰ×Ѫ²¡¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó > »ùÒòÐÞÊΰ×Ѫ²¡¶¯ÎïÄ£×Ó

ǰÑÔ

°×Ѫ²¡(leukemia)ÊÇÔìѪ×éÖ¯µÄ¶ñÐÔÔöÖ³ÐÔ¼²²¡ £¬ÆäÌØµãÊǹÇËè¼°ÆäËûÔìѪ×éÖ¯Öдó×ÚÎÞºËϸ°ûÎÞÏÞÖÆÔöÉú £¬½øÈëÍâÖÜѪҺ £¬ÁÙ´²ÌåÏÖÒÔ¹ÇË衢Ƣ¡¢¸ÎµÈÔìѪÆ÷¹ÙÖеİ×Ѫ²¡Ï¸°û¶ñÐÔÔöÉúÓëÖ×´ó £¬²¢½þÈóµ½È«Éí¸÷×éÖ¯ÔàÆ÷ÖÐ £¬°éÓвî±ðˮƽµÄѪÐé¡¢³öѪ¡¢Ñ¬È¾·¢ÈÈÒÔ¼°¹Ç÷ÀÌÛÍ´¡£°×Ѫ²¡µÄ·¢²¡ÂʺÍéæÃüÂÊÖðÄêÔöÌí £¬¾Ó35ËêÒÔÏÂÇàÉÙÄê¶ñÐÔÖ×ÁöµÄÊ×λ¡£Òò´Ë £¬ÖƱ¸ÏìÓ¦µÄ¶¯ÎïÄ£×Ó¶ÔÆäÑо¿¾ßÓÐÖ÷ÒªµÄÒâÒå¡£¾ø´ó´ó¶¼ÈËÀà°×Ѫ²¡¿ÉÒÔÓû¯Ñ§£¨ÈçÉÕ»¯¼Á£©¡¢ÎïÀí£¨ÈçµçÀë·øÉ䣩¡¢ÉúÎÈ練ת¼²¡¶¾£©ÒÔ¼°×ª»ùÒòÒªÁì £¬ÔÚ²î±ð¶¯ÎСÊó¡¢ëàÊó¡¢´óÊó¡¢Ã¨¡¢Å£¡¢³¤±ÛÔ³µÈ£©ÖÐÓÕ·¢°×Ѫ²¡ £¬½¨É趯ÎïÄ£×Ó¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

bcr/ablת»ùÒòСÊóÄ£×Ó£ºÍ¨¹ý¿Ë¡ÆÊÎöСÊóTec»ùÒòµÄÆô¶¯×ÓÐòÁк͹¦Ð§ £¬·¢Ã÷ÓÉTecÆô¶¯×Óµ÷¿ØµÄ»ùÒò½öÌØÒìÐԵرí´ïÔÚÔìѪ¸Éϸ °ûµÄϸ°ûÖÊÖС£½ÓÄÉСÊóµÄTec»ùÒòµÄÆô¶¯×ÓÐòÁÐ £¬ÖƱ¸×ª»ùÒòÔØÌå £¬Ð¯´ø°×Ѫ²¡Ïà¹Ø»ùÒòbcr/abl £¬ÖƱ¸×ª»ùÒò¶¯Îת»ùÒòСÊóÊ×ÏÈ·ºÆðÁ£Ï¸°ûÒì³£ÔöÉú¡¢¸ßѪС°åѪ֢ £¬¾­Ò»×¼Ê±¼äºó±¬·¢¹ÇËèÔöÖ³×ÛºÏÕ÷ £¬ºÍÈËCML¼«ÎªÏàËÆ¡£ÆäÖÐÓÐת»ùÒòÊóÔÚ³öÉúºó¼´ÌåÏÖΪ¼±ÐÔ°×Ѫ²¡ £¬µ«ËüÃǵÄ×Ó´ú¾­ÓÉÒ»¶ÎDZÔÚÆÚºóÌåÏÖ¹ÇËèÔöÉú×ÛºÏÕ÷¡£ÁíÍâÒ»ÖÖת»ùÒòСÊóÊǸ߱í´ïÒ»Á¬»î»¯µÄÍ»±äStat5 £¬´ËÍ»±äµÄstat5Я´ø2¸öÍ»±äλµã £¬¿ÉÒÔºÍÄÚÔ´ÐÔstat5ÍŽá £¬Ðγɶþ¾ÛÌå £¬Ò»Á¬»î»¯¡£ÕâÖÖСÊóÉú³¤·¢ÓýÀú³ÌÖб¬·¢°×Ѫ²¡¡£ÉÐÓÐÍ»±ä»ùÒòÇÃÈë(knock-in)Ä£×Ó¡£Èç £¬SHP-2D61G¡¢SHP-2E76K»ùÒòÇÃÈëСÊó £¬¾ù±¬·¢°×Ѫ²¡¡£

¡¾Ä£×ÓÌØµã¡¿£º

ʹÓòî±ðµÄÆô¶¯×ÓÒѽ¨ÉèÆð¼¸¸öÄÜÄ£ÄâÈËCMLµÄת»ùÒòСÊóƷϵ¡£Ó뷴ת¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓÏà±È £¬×ª»ùÒòСÊóÄ£×ÓÓÐÒÔϼ¸¸öÓŵ㣺¢Ùbcr/abl»ùÒò×÷Ϊת»ùÒòСÊóµÄÒ»²¿·ÖÔÚÌåÄÚ±í´ï £¬¸üÄÜ׼ȷµØÄ£ÄâÈËCML£»¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓÔÚϸ°û×÷Óý¡¢ÒÆÖ²Àú³ÌÊÜÐí¶àϸ°ûÒò×ÓµÄÓ°Ïì £¬ÕâЩϸ°ûÒò×Ӻʹ¦Öóͷ£ÊÜÌåÊóµÄÆäËûÒòËØ¶¼¶Ô¼²²¡µÄ±íÐÍÓнϴóµÄÓ°Ïì¡£¢Úbcr/ablת»ùÒòÊó¿ÉÒÔ´«´ú £¬¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓÐëÖØÐ½¨Éè¡£¢Ûת»ùÒòCMLÄ£×ÓÓÐÒ»¶¨µÄDZÔÚÆÚ £¬ÕâÓëÈ˵ÄCML¼«ÎªÏàËÆ£»¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓDZÔÚÆÚ¶Ì £¬µ¹ÔËÓÚÈËCML·¢²¡Ç°»úÖÆµÄÑо¿¡£¢Üת»ùÒòÊóµÄCMLÓÐÀàËÆÓÚÈËCMLµÄµ¥¿Ë¡ÐÔ £¬¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²ÊóµÄCMLÊǶà¿Ë¡µÄ¡£×ª»ùÒòCMLÒ²±£´æÒ»Ð©Èõµã£º¢Ùת»ùÒò¶¯ÎïµÄÿһ¸öϸ°û¶¼ÓÐbcr/abl»ùÒòµÄ±í´ï £¬¶øÈ˵ÄCMLÖ»ÔÚÔìѪ¸Éϸ°ûºÍ×æÏ¸°ûÖбí´ï £¬Õâ»òÐí»áÓ°ÏìCMLµÄ²¡ÀíÌØÕ÷ºÍÖÎÁÆÇéÐΣ»¢ÚSHP-2061GСÊóÕý³£Éú³¤·¢ÓýÀú³ÌÖнö±¬·¢ËèϵÔöÖ³²¡ £¬µ«·øÕպ󱬷¢°×Ѫ²¡¼°ÆäËûÖ×Áö£»¢ÛSHP-2E76KÊÇÌõ¼þÐÔÇÃÈëСÊó £¬Åß̥СÊóÈôÊÇѪҺϵͳ±í´ïSHP-2E76KÍ»±ä»áµ¼ÖÂСÊóÅßÌ¥ÖÂËÀ £¬ÒÔÊǽöÔÚСÊó³öÉúºó £¬ÓÃPoly I:CÓÕµ¼ÑªÒºÏµÍ³Cre±í´ï £¬µ¼ÖÂСÊóÔìѪ¸Éϸ°û»òÕß×æÏ¸°û±í´ïSHP-2E76KÍ»±äÂÑ°× £¬Ð¡Ê󱬷¢°×Ѫ²¡¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

ÓÉÓÚbcr/ablת»ùÒòСÊóÄ£×Ó±£´æÒÅ´«»¹²»·óÎȹ̡¢Ä£ÄâCML»¹²»·ó׼ȷµÈÈõµã £¬Òò´Ë»¹ÐèҪѰÕÒ¸üºÏÊÊµÄÆô¶¯×Ó £¬Ì½Ë÷¸ü±ãµ±µÄת»ùÒò¶¯ÎïÒªÁì £¬ÊµÑé¸ü½üËÆµÄ¶¯ÎïÆ·ÖÖ¡£ÏÖÔÚÖ÷ÒªÓÃÓÚÒÔÏÂ3·½ÃæµÄÑо¿£ºÖ¤ÊµCMLÊÇ·ñÔìѪ¸Éϸ°ûÔ´ÐÔ £¬Ñо¿bcr/abl»ùÒòÓëÆäËûÏà¹Ø»ùÒò¶Ô°×Ѫ²¡ÅäºÏÓ°Ïì £¬ÖÎÁÆÒ©ÎïµÄɸѡ¡£SHP-2061G¼°SHP-2E76KÇÃÈëСÊóÊǺܺõİ×Ѫ²¡¶¯ÎïÄ£×Ó £¬µ«ÐèÒªÉÌÆ·»¯¡£

 

²Î¿¼ÎÄÏ×£º

1.µËÑï¼Î £¬ÐìÒèÖ¥ £¬Â¦ÊÀ·æ£®¼±ÐÔËèÐÔ°×Ѫ²¡SCIDСÊóÄ£×ӵĽ¨Éè¼°Åжϣ®ÏÖ´úÉúÎïҽѧϣÍû £¬2008,8(1): 53-55

2.ÖìÓñ·å £¬ÍõÔªÕ¼ £¬ÃÏ·²Ò壮BCR/ABLת»ùÒò¶¯ÎïÄ£×ÓÑо¿Ï£Íû¼°Ó¦Óã®ÖйúʵÑéѪҺѧÔÓÖ¾ £¬2011,19 (6):1532-1535

3.Áõΰ £¬¼¾Ã÷´º £¬Àîºñ´ï. ÈËÂýÐÔÁ£Ï¸°û°×Ѫ²¡¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®Öйú½ÏÁ¿Ò½Ñ§ÔÓÖ¾ £¬2005,15 (1):55-58

4.ÀîÀöϼ £¬ÌÀÓÀÃñ £¬¹ËΰÖÒ £¬µÈ£®¼±ÐÔBÁܰÍϸ°û°×Ѫ²¡¶¯ÎïÄ£×ӵĽ¨Éè. Õã½­´óѧѧ±¨£ºÒ½Ñ§°æ £¬2008,37(5): 511-514

5.ÑîÏþöï. Ö£¾þËÉ £¬ÕÅР£¬µÈ£®GITR¿¹Ìå¶ÔL615°×Ѫ²¡ÒÖÖÆ×÷ÓõÄʵÑéÑо¿. µÚÈý¾üÒ½´óѧѧ±¨ £¬2006,28 (18):1837-1841

6.ÖÜÏþÑà £¬×ÞÁÕ£®°×Ѫ²¡Ð¡ÊóÄ£×ӵĽ¨ÉèÓëÓ¦ÓÃÏÖ×´£®·Ö×ÓÕï¶ÏÓëÖÎÁÆÔÓÖ¾ £¬2011,3 (3):212-216

7.Ohsugi T, Yamaguchi K, Kumasaka T, et a]_ Rapid tumor death model for evalualion of new therapeutic agents for adult T-cell leukemia. Lab Invest,2004, 84 (2): 263-266

8.Ramshaw HS, Bardy PG, Lee MA, el al. Chronic myelomoaocylic leukemia requires granulocyte­ macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol,2002,30(10):1124-1131

9.Wang S, Yu WM, Zhang W, et al. Noonan syndrome/ leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN 11) enhance cell migration and angiogenesis. J Biol Chem, 2009, 284 (2):913-920

10.Xu D,Wang S,Yu  WM,et al. A germline  gain-of­function mutation in Ptpn 11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hemalopoielic stem cells. Blood, 2010, 116(18):3611-3621

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó > »ùÒòÐÞÊΰ×Ѫ²¡¶¯ÎïÄ£×Ó
»ùÒòÐÞÊΰ×Ѫ²¡¶¯ÎïÄ£×Ó

ǰÑÔ

°×Ѫ²¡(leukemia)ÊÇÔìѪ×éÖ¯µÄ¶ñÐÔÔöÖ³ÐÔ¼²²¡ £¬ÆäÌØµãÊǹÇËè¼°ÆäËûÔìѪ×éÖ¯Öдó×ÚÎÞºËϸ°ûÎÞÏÞÖÆÔöÉú £¬½øÈëÍâÖÜѪҺ £¬ÁÙ´²ÌåÏÖÒÔ¹ÇË衢Ƣ¡¢¸ÎµÈÔìѪÆ÷¹ÙÖеİ×Ѫ²¡Ï¸°û¶ñÐÔÔöÉúÓëÖ×´ó £¬²¢½þÈóµ½È«Éí¸÷×éÖ¯ÔàÆ÷ÖÐ £¬°éÓвî±ðˮƽµÄѪÐé¡¢³öѪ¡¢Ñ¬È¾·¢ÈÈÒÔ¼°¹Ç÷ÀÌÛÍ´¡£°×Ѫ²¡µÄ·¢²¡ÂʺÍéæÃüÂÊÖðÄêÔöÌí £¬¾Ó35ËêÒÔÏÂÇàÉÙÄê¶ñÐÔÖ×ÁöµÄÊ×λ¡£Òò´Ë £¬ÖƱ¸ÏìÓ¦µÄ¶¯ÎïÄ£×Ó¶ÔÆäÑо¿¾ßÓÐÖ÷ÒªµÄÒâÒå¡£¾ø´ó´ó¶¼ÈËÀà°×Ѫ²¡¿ÉÒÔÓû¯Ñ§£¨ÈçÉÕ»¯¼Á£©¡¢ÎïÀí£¨ÈçµçÀë·øÉ䣩¡¢ÉúÎÈ練ת¼²¡¶¾£©ÒÔ¼°×ª»ùÒòÒªÁì £¬ÔÚ²î±ð¶¯ÎСÊó¡¢ëàÊó¡¢´óÊó¡¢Ã¨¡¢Å£¡¢³¤±ÛÔ³µÈ£©ÖÐÓÕ·¢°×Ѫ²¡ £¬½¨É趯ÎïÄ£×Ó¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

bcr/ablת»ùÒòСÊóÄ£×Ó£ºÍ¨¹ý¿Ë¡ÆÊÎöСÊóTec»ùÒòµÄÆô¶¯×ÓÐòÁк͹¦Ð§ £¬·¢Ã÷ÓÉTecÆô¶¯×Óµ÷¿ØµÄ»ùÒò½öÌØÒìÐԵرí´ïÔÚÔìѪ¸Éϸ °ûµÄϸ°ûÖÊÖС£½ÓÄÉСÊóµÄTec»ùÒòµÄÆô¶¯×ÓÐòÁÐ £¬ÖƱ¸×ª»ùÒòÔØÌå £¬Ð¯´ø°×Ѫ²¡Ïà¹Ø»ùÒòbcr/abl £¬ÖƱ¸×ª»ùÒò¶¯Îת»ùÒòСÊóÊ×ÏÈ·ºÆðÁ£Ï¸°ûÒì³£ÔöÉú¡¢¸ßѪС°åѪ֢ £¬¾­Ò»×¼Ê±¼äºó±¬·¢¹ÇËèÔöÖ³×ÛºÏÕ÷ £¬ºÍÈËCML¼«ÎªÏàËÆ¡£ÆäÖÐÓÐת»ùÒòÊóÔÚ³öÉúºó¼´ÌåÏÖΪ¼±ÐÔ°×Ѫ²¡ £¬µ«ËüÃǵÄ×Ó´ú¾­ÓÉÒ»¶ÎDZÔÚÆÚºóÌåÏÖ¹ÇËèÔöÉú×ÛºÏÕ÷¡£ÁíÍâÒ»ÖÖת»ùÒòСÊóÊǸ߱í´ïÒ»Á¬»î»¯µÄÍ»±äStat5 £¬´ËÍ»±äµÄstat5Я´ø2¸öÍ»±äλµã £¬¿ÉÒÔºÍÄÚÔ´ÐÔstat5ÍŽá £¬Ðγɶþ¾ÛÌå £¬Ò»Á¬»î»¯¡£ÕâÖÖСÊóÉú³¤·¢ÓýÀú³ÌÖб¬·¢°×Ѫ²¡¡£ÉÐÓÐÍ»±ä»ùÒòÇÃÈë(knock-in)Ä£×Ó¡£Èç £¬SHP-2D61G¡¢SHP-2E76K»ùÒòÇÃÈëСÊó £¬¾ù±¬·¢°×Ѫ²¡¡£

¡¾Ä£×ÓÌØµã¡¿£º

ʹÓòî±ðµÄÆô¶¯×ÓÒѽ¨ÉèÆð¼¸¸öÄÜÄ£ÄâÈËCMLµÄת»ùÒòСÊóƷϵ¡£Ó뷴ת¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓÏà±È £¬×ª»ùÒòСÊóÄ£×ÓÓÐÒÔϼ¸¸öÓŵ㣺¢Ùbcr/abl»ùÒò×÷Ϊת»ùÒòСÊóµÄÒ»²¿·ÖÔÚÌåÄÚ±í´ï £¬¸üÄÜ׼ȷµØÄ£ÄâÈËCML£»¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓÔÚϸ°û×÷Óý¡¢ÒÆÖ²Àú³ÌÊÜÐí¶àϸ°ûÒò×ÓµÄÓ°Ïì £¬ÕâЩϸ°ûÒò×Ӻʹ¦Öóͷ£ÊÜÌåÊóµÄÆäËûÒòËØ¶¼¶Ô¼²²¡µÄ±íÐÍÓнϴóµÄÓ°Ïì¡£¢Úbcr/ablת»ùÒòÊó¿ÉÒÔ´«´ú £¬¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓÐëÖØÐ½¨Éè¡£¢Ûת»ùÒòCMLÄ£×ÓÓÐÒ»¶¨µÄDZÔÚÆÚ £¬ÕâÓëÈ˵ÄCML¼«ÎªÏàËÆ£»¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓDZÔÚÆÚ¶Ì £¬µ¹ÔËÓÚÈËCML·¢²¡Ç°»úÖÆµÄÑо¿¡£¢Üת»ùÒòÊóµÄCMLÓÐÀàËÆÓÚÈËCMLµÄµ¥¿Ë¡ÐÔ £¬¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²ÊóµÄCMLÊǶà¿Ë¡µÄ¡£×ª»ùÒòCMLÒ²±£´æÒ»Ð©Èõµã£º¢Ùת»ùÒò¶¯ÎïµÄÿһ¸öϸ°û¶¼ÓÐbcr/abl»ùÒòµÄ±í´ï £¬¶øÈ˵ÄCMLÖ»ÔÚÔìѪ¸Éϸ°ûºÍ×æÏ¸°ûÖбí´ï £¬Õâ»òÐí»áÓ°ÏìCMLµÄ²¡ÀíÌØÕ÷ºÍÖÎÁÆÇéÐΣ»¢ÚSHP-2061GСÊóÕý³£Éú³¤·¢ÓýÀú³ÌÖнö±¬·¢ËèϵÔöÖ³²¡ £¬µ«·øÕպ󱬷¢°×Ѫ²¡¼°ÆäËûÖ×Áö£»¢ÛSHP-2E76KÊÇÌõ¼þÐÔÇÃÈëСÊó £¬Åß̥СÊóÈôÊÇѪҺϵͳ±í´ïSHP-2E76KÍ»±ä»áµ¼ÖÂСÊóÅßÌ¥ÖÂËÀ £¬ÒÔÊǽöÔÚСÊó³öÉúºó £¬ÓÃPoly I:CÓÕµ¼ÑªÒºÏµÍ³Cre±í´ï £¬µ¼ÖÂСÊóÔìѪ¸Éϸ°û»òÕß×æÏ¸°û±í´ïSHP-2E76KÍ»±äÂÑ°× £¬Ð¡Ê󱬷¢°×Ѫ²¡¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

ÓÉÓÚbcr/ablת»ùÒòСÊóÄ£×Ó±£´æÒÅ´«»¹²»·óÎȹ̡¢Ä£ÄâCML»¹²»·ó׼ȷµÈÈõµã £¬Òò´Ë»¹ÐèҪѰÕÒ¸üºÏÊÊµÄÆô¶¯×Ó £¬Ì½Ë÷¸ü±ãµ±µÄת»ùÒò¶¯ÎïÒªÁì £¬ÊµÑé¸ü½üËÆµÄ¶¯ÎïÆ·ÖÖ¡£ÏÖÔÚÖ÷ÒªÓÃÓÚÒÔÏÂ3·½ÃæµÄÑо¿£ºÖ¤ÊµCMLÊÇ·ñÔìѪ¸Éϸ°ûÔ´ÐÔ £¬Ñо¿bcr/abl»ùÒòÓëÆäËûÏà¹Ø»ùÒò¶Ô°×Ѫ²¡ÅäºÏÓ°Ïì £¬ÖÎÁÆÒ©ÎïµÄɸѡ¡£SHP-2061G¼°SHP-2E76KÇÃÈëСÊóÊǺܺõİ×Ѫ²¡¶¯ÎïÄ£×Ó £¬µ«ÐèÒªÉÌÆ·»¯¡£

 

²Î¿¼ÎÄÏ×£º

1.µËÑï¼Î £¬ÐìÒèÖ¥ £¬Â¦ÊÀ·æ£®¼±ÐÔËèÐÔ°×Ѫ²¡SCIDСÊóÄ£×ӵĽ¨Éè¼°Åжϣ®ÏÖ´úÉúÎïҽѧϣÍû £¬2008,8(1): 53-55

2.ÖìÓñ·å £¬ÍõÔªÕ¼ £¬ÃÏ·²Ò壮BCR/ABLת»ùÒò¶¯ÎïÄ£×ÓÑо¿Ï£Íû¼°Ó¦Óã®ÖйúʵÑéѪҺѧÔÓÖ¾ £¬2011,19 (6):1532-1535

3.Áõΰ £¬¼¾Ã÷´º £¬Àîºñ´ï. ÈËÂýÐÔÁ£Ï¸°û°×Ѫ²¡¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®Öйú½ÏÁ¿Ò½Ñ§ÔÓÖ¾ £¬2005,15 (1):55-58

4.ÀîÀöϼ £¬ÌÀÓÀÃñ £¬¹ËΰÖÒ £¬µÈ£®¼±ÐÔBÁܰÍϸ°û°×Ѫ²¡¶¯ÎïÄ£×ӵĽ¨Éè. Õã½­´óѧѧ±¨£ºÒ½Ñ§°æ £¬2008,37(5): 511-514

5.ÑîÏþöï. Ö£¾þËÉ £¬ÕÅР£¬µÈ£®GITR¿¹Ìå¶ÔL615°×Ѫ²¡ÒÖÖÆ×÷ÓõÄʵÑéÑо¿. µÚÈý¾üÒ½´óѧѧ±¨ £¬2006,28 (18):1837-1841

6.ÖÜÏþÑà £¬×ÞÁÕ£®°×Ѫ²¡Ð¡ÊóÄ£×ӵĽ¨ÉèÓëÓ¦ÓÃÏÖ×´£®·Ö×ÓÕï¶ÏÓëÖÎÁÆÔÓÖ¾ £¬2011,3 (3):212-216

7.Ohsugi T, Yamaguchi K, Kumasaka T, et a]_ Rapid tumor death model for evalualion of new therapeutic agents for adult T-cell leukemia. Lab Invest,2004, 84 (2): 263-266

8.Ramshaw HS, Bardy PG, Lee MA, el al. Chronic myelomoaocylic leukemia requires granulocyte­ macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol,2002,30(10):1124-1131

9.Wang S, Yu WM, Zhang W, et al. Noonan syndrome/ leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN 11) enhance cell migration and angiogenesis. J Biol Chem, 2009, 284 (2):913-920

10.Xu D,Wang S,Yu  WM,et al. A germline  gain-of­function mutation in Ptpn 11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hemalopoielic stem cells. Blood, 2010, 116(18):3611-3621

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿